Затова, по време на оттеглянето, мнението на CHMP е било, че ползите от IPLEX не са представени достатъчно добре и не надвишават известните рискове.
Therefore, at the time of the withdrawal, the CHMP’ s view was that the benefit of IPLEX had not been sufficiently demonstrated and did not outweigh the identified risks.